Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc CRDL


Primary Symbol: T.CRDL

Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc > New Buy recommendation with $15.77 Target
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Comment by Youhillmanon Jun 23, 2021 11:28am
148 Views
Post# 33434378

RE:New Buy recommendation with $15.77 Target

RE:New Buy recommendation with $15.77 Target

Just received a more complete analyst report vs. the link I sent earlier today, I hope you find it beneficial!


Youhillman wrote:

Just caught the attached as it was published today. 

Solid recommendation by this German firm where CRDL is listed. It's the highest target price I have seen to date.

Personally I'm waiting for the NASDAQ listing news, it could be this month or early next month based on comments recently made by the CEO, in fact he is doing a Renmark call today at noon, hopefully we get an update.  

A NASDAQ listing will double the current price of CRDL.

I'm long on CRDL!

https://www.marketscreener.com/quote/stock/CARDIOL-THERAPEUTICS-INC-49649129/news/Original-Research-nbsp-Cardiol-Therapeutics-von-GBC-AG-BUY-35681247/
 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities